Related Experiment Videos
Alzheimer's disease: Key developments support promising perspectives for therapy
1Department of Neuroscience, San Raffaele Institute and Vita-Salute San Raffaele University, via Olgettina 58, 20132, Milan, Italy.
Abstract:
Alzheimer's is the neurodegenerative disease affecting the largest number of patients in the world. In spite of the intense research of the last decades, progress about its knowledge and therapy was limited. In particular, various cytotoxic processes remained debated, while the few drugs approved for therapy were of only marginal relevance. Recent studies have identified key aspects of the disease, such as the mechanisms governing the development of pathology. In order to operate the Aβ peptide, known as the key factor, requires a complex assembled by its high affinity binding to PrPc, a cell surface prion protein, and mGluR5, a metabotropic glutamate receptor. Aβ and its associates bind also phosphorylated tau transferred to the extracellular space, with final activation of intracellular cytotoxic signals. Pathology is further affected by factors (including genes, receptors and their agonists) and by glial cells governing (via vesicles, cytokines and enzymes) cell immunology, inflammation and oxidative stress. Concomitant to pathology studies, strong attempts have been made for the development of new, effective therapies. Critical for this are biomarkers, by which Alzheimer's patients are recognized even before appearance of their symptoms. The question was whether patients take advantage from drugs not yet approved. The latter, first identified in mice, were found effective also in men, however only before appearance or at early stage of the disease. In other words, the drugs not yet approved induce effective protection of patients still healthy or in a preliminary stage of the disease. In contrast, developed Alzheimer's disease is practically irreversible.
Insights
New Alzheimer's research reveals that unapproved drugs show effectiveness in protecting individuals before symptoms appear or in the early stages. Developed Alzheimer's disease remains largely irreversible, highlighting the importance of early intervention.
Area of Science:
- Neurodegenerative diseases
- Alzheimer's disease pathology
- Molecular mechanisms of neurodegeneration
Background:
- Alzheimer's disease (AD) is a leading cause of neurodegeneration globally, with limited therapeutic progress despite extensive research.
- Key pathological mechanisms, including amyloid-beta (Aβ) peptide interactions with cellular prion protein (PrPc) and mGluR5, are crucial in AD development.
- Extracellular tau pathology and glial cell-mediated immune responses, inflammation, and oxidative stress significantly influence AD progression.
Purpose of the Study:
- To elucidate the molecular pathways driving Alzheimer's disease pathology.
- To investigate the potential of novel therapeutic strategies targeting early-stage AD.
- To evaluate the efficacy of biomarkers for early AD detection and intervention.
Main Methods:
- Analysis of Aβ peptide interactions with PrPc and mGluR5.
- Investigation of tau pathology in the extracellular space.
- Assessment of glial cell involvement in immune, inflammatory, and oxidative stress responses.
- Evaluation of therapeutic efficacy of unapproved drugs in preclinical and early clinical stages.
Main Results:
- Identified a complex mechanism involving Aβ, PrPc, and mGluR5 in AD pathogenesis.
- Demonstrated that unapproved drugs are effective in protecting against AD pathology in mice and humans, but only before symptom onset or in early disease stages.
- Confirmed that advanced Alzheimer's disease is practically irreversible.
Conclusions:
- Early detection and intervention are critical for effective Alzheimer's disease treatment.
- Unapproved drugs hold promise for prophylactic or early-stage intervention against Alzheimer's disease.
- Further research into AD molecular mechanisms is essential for developing more effective therapies.